Click here if you are having trouble viewing this message
ASHM email alert banner
The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) are pleased to offer webinar access to selected education seminars from the Kirby Institute Seminar Series in June 2018.

Enhancing liver disease screening and hepatitis C treatment uptake among people who inject drugs

Alison Marshall
Postdoctoral Fellow, Viral Hepatitis Clinical Research Program, Kirby Institute

1:00pm – 2:00pm AEST   Tuesday 19 June 2018

ABSTRACT
To achieve WHO’s hepatitis C virus (HCV) elimination targets by 2030, liver disease assessment and treatment uptake among people who inject drugs (PWID) will need to be substantially increased globally. Enhanced knowledge of the remaining barriers to HCV-related care at the patient, provider, and system levels is thus a necessity. This seminar will present evidence from the LiveRLife cohort – a healthy liver campaign targeted to PWID who attend drug and alcohol centres in New South Wales, Australia – highlighting remaining gaps in HCV and liver disease knowledge among PWID, including PWID understanding of liver disease assessment results (i.e. transient elastography score). This seminar will also speak to system-level barriers, namely, restrictions for accessing reimbursed direct-acting antiviral therapies (DAAs) in Canada and Europe (e.g. drug and alcohol use restrictions) with implications for PWID populations specifically.
ABOUT YOUR SPEAKER
Ms Alison Marshall commenced her PhD studies with the Viral Hepatitis Clinical Research Program at the Kirby Institute in 2014 and is currently an Associate Lecturer at the Kirby Institute and the Centre for Social Research in Health, partly funded through a Fellowship from the Canadian Institutes of Health Research and the Canadian Network on Hepatitis C.